Rising levels of antimicrobial resistance pose serious dangers to patients, population health, food security, and economic stability worldwide. In response to this threat, the United Nations and the World Health Organization have called for multisectoral, multidisciplinary action, recognizing that human, animal, and environmental health are interdependent. Although the pharmaceutical industry clearly has a leading role in developing novel antimicrobials and vaccines, it is also active in many areas supporting antimicrobial stewardship. This article describes why pharmaceutical companies invest in antimicrobial stewardship, outlines why they are well suited to help address this issue, and provides examples of how the pharmaceutical industry can support the responsible use of antimicrobials. Merck & Co., Inc. (Kenilworth, NJ, USA), a large, globally operating pharmaceutical company that develops and markets both human and veterinary antimicrobials and vaccines is used as a case study for illustrating industry involvement in antimicrobial stewardship efforts.

中文翻译：

---

制药公司在抗菌素管理中的作用：一个案例研究。

抗菌素耐药性水平的上升对全世界的患者，人口健康，食品安全和经济稳定构成严重威胁。针对这种威胁，联合国和世界卫生组织呼吁采取多部门，多学科的行动，认识到人类，动物和环境健康是相互依存的。尽管制药业显然在开发新型抗菌剂和疫苗方面起着领导作用，但它在支持抗菌素管理的许多领域也很活跃。本文介绍了制药公司为何对抗菌素管理进行投资，概述了为什么它们非常适合帮助解决此问题，并提供了制药行业如何支持负责任地使用抗菌素的示例。默克公司（美国，新泽西州，肯尼沃思）